Drugs & Targets EC approves Cabometyx as a second-line treatment for radioactive iodine-refractory differentiated thyroid cancer May 06, 2022Vol.48 No.18
Drugs & Targets Myriad Genetics expands partnership with Intermountain Precision Genomics, adding liquid biopsy therapy selection offering May 06, 2022Vol.48 No.18
Drugs & Targets Aadi Bioscience issues unique permanent J-code for Fyarro from CMS May 06, 2022Vol.48 No.18
Drugs & Targets EMA CHMP adopts positive opinion for Tabrecta in METex14 advanced NSCLC April 29, 2022Vol.48 No.17
Drugs & Targets Portage Biotech, NCI, Stimunity enter cooperative R&D agreement to develop STING agonists and anti-RAGE agents for cancer vaccines April 29, 2022Vol.48 No.17
Drugs & Targets FDA grants clearance to ClearPoint Neuro’s SmartFrame Array version 1.1 April 29, 2022Vol.48 No.17
Drugs & Targets ODAC votes unanimously in support of use of randomized data in PI3K inhibitor trials April 22, 2022Vol.48 No.16
Drugs & Targets FDA grants priority review to Enhertu in previously treated HER2-mutant metastatic NSCLC April 22, 2022Vol.48 No.16
Drugs & Targets FDA fast tracks targeted breast cancer immunotherapy Bria-IMT April 15, 2022Vol.48 No.15
